Evidence map›Paper›PMID 39150481›Full record

ArticleJournal of autism and developmental disorders2025

Reported Barriers and Facilitators for Autistic Individuals, Persons with Other Intellectual and Developmental Disabilities, and Their Caregivers to Receive the COVID-19 Vaccine: A Pilot Study.

Annie W Resnikoff, Valerie Colantuono, Andrea Trubanova Wieckowski, Esther Chernak, Jennifer Plumb, Maurice Baynard, Elisabeth Sheridan, Diana L Robins

Abstract read
In one paragraph

Article in Journal of autism and developmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annie W ResnikoffA.J. Drexel Autism Institute, 3020 Market Street, Philadelphia, PA, 19104, USA. ar3767@drexel.edu.ORCID http://orcid.org/0009-0009-9219-495X
Valerie ColantuonoA.J. Drexel Autism Institute, 3020 Market Street, Philadelphia, PA, 19104, USA.
Andrea Trubanova WieckowskiA.J. Drexel Autism Institute, 3020 Market Street, Philadelphia, PA, 19104, USA.
Esther ChernakDrexel University Dornsife School of Public Health, 3215 Market St., Philadelphia, PA, USA.
Jennifer PlumbA.J. Drexel Autism Institute, 3020 Market Street, Philadelphia, PA, 19104, USA.
Maurice BaynardAcademy of Natural Sciences of Drexel University, Philadelphia, PA, USA.
Elisabeth SheridanA.J. Drexel Autism Institute, 3020 Market Street, Philadelphia, PA, 19104, USA.
Diana L RobinsA.J. Drexel Autism Institute, 3020 Market Street, Philadelphia, PA, 19104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autistic individuals and persons with other intellectual or developmental disabilities (IDD) may experience challenges in social engagement, sensory processing, and behavior rigidity. This population is more likely to face barriers to successful preventative healthcare, including vaccines, compared to neurotypical peers. Autistic individuals and persons with other IDD may be at greater risk for COVID-19 infection due to sensory dysregulation that interferes with mitigation such as wearing masks, and challenges in social communication that impose difficulties in understanding and adhering to prevention measures. Adaptations are needed to make vaccine opportunities more accessible for neurodivergent individuals. A series of seven Sensory-Friendly COVID-19 Vaccine Clinics (SFVCs) were conducted between December 2021 and August 2022 in collaboration with the A.J. Drexel Autism Institute and the Academy of Natural Sciences of Drexel University. SFVCs examined perceived barriers and facilitators to vaccine experiences, based on feedback from autistic individual/persons with IDD and their caregivers. Surveys were administered to autistic individuals/persons with IDD or their caregivers (n = 35) from the larger sample who attended the clinic; 18 participants also complete a supplemental interview. Scaled survey questions were analyzed to determine the acceptability of the SFVCs. Open-ended survey questions and interview responses were coded thematically to identify barriers, facilitators, and areas of improvement. All individuals who came to a SFVC with intent to be vaccinated were successfully administered a COVID-19 vaccine. More than 90% of participants reported that experiences at the SFVCs were positive, promoted retention, and they would recommend clinics to others. Staff clinical expertise, sensory-friendly elements, and hosting clinics at a neutral location (free from past medical history) served as facilitators to successful vaccine administration, whereas factors such as ill-equipped pharmacy staff, behavioral challenges, and logistical issues may serve as barriers. Incorporating reported barriers, facilitators, and accommodations of SFVC experiences may lead to more successful preventative healthcare processes for neurodivergent individuals.

Indexed as

Autistic DisorderCaregiversCOVID-19COVID-19 VaccinesDevelopmental DisabilitiesHealth Services AccessibilityIntellectual DisabilityPatient Acceptance of Health CareAdultFemaleHumansMaleMiddle AgedPilot ProjectsSARS-CoV-2Young AdultCOVID-19 VaccinesAutism spectrumMedicalPsychosocial or behavioral interventionsSensory perception

Identifiers

PMID39150481
PMCPMC12589220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.